EBO2

EBO2 is a healthcare and regenerative-medicine company built around the EBO2 blood-treatment system, a device-based extracorporeal blood oxygenation and ozonation procedure developed by Dr. Louie Yu. The company has been described as the provider of a second-generation, high-volume blood gas exchange and filtration technology intended to treat 5-7 liters of blood using medical ozone within a closed extracorporeal circuit. EBO2 appears to operate primarily as a commercial medical-technology and clinic-enablement business rather than as a traditional drug-development biotech with a disclosed therapeutic pipeline. The business was acquired by Full Alliance Group and has been referenced as a wholly owned subsidiary of that company. Its market presence is concentrated in regenerative, functional, and integrative medicine settings where EBO2/EBOO is offered as a commercial treatment service and technology platform.